Descriptive Observational Study ALK-2016-CPHG

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

NCT04111705 ·Status: COMPLETED ·Phase: PHASE2

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

NCT01300429 ·Status: COMPLETED

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

NCT03647111 ·Status: RECRUITING

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

NCT01945021 ·Status: COMPLETED ·Phase: PHASE2

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

NCT05167500 ·Status: COMPLETED

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

NCT05792644 ·Status: COMPLETED ·Phase: NA

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

NCT03672643 ·Status: TERMINATED ·Phase: PHASE4

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 ·Status: WITHDRAWN ·Phase: PHASE4

Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation

NCT01637597 ·Status: UNKNOWN

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

NCT03535740 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

NCT02034981 ·Status: COMPLETED ·Phase: PHASE2

Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1

NCT04718012 ·Status: COMPLETED

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

NCT02336451 ·Status: COMPLETED ·Phase: PHASE2

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

NCT01801111 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

NCT01685138 ·Status: COMPLETED ·Phase: PHASE2

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NCT01639001 ·Status: COMPLETED ·Phase: PHASE3

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

NCT05014464 ·Status: RECRUITING ·Phase: PHASE2

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894 ·Status: COMPLETED

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016 ·Status: RECRUITING ·Phase: PHASE1

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

NCT01121588 ·Status: TERMINATED ·Phase: PHASE1

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT04632758 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

NCT01685060 ·Status: COMPLETED ·Phase: PHASE2